Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Designation of Prescription Drugs Proceeding as Planned: Korosho
January 24, 2005
- WEBSITE NEWS
January 24, 2005
- Full-scale Discussions on Revision of Medical Service Law to Begin in Autumn
January 24, 2005
- NEW PRODUCTS
January 24, 2005
- Opinions on Revisions of ADR, Malfunctions Reporting Criteria Sought: Korosho
January 24, 2005
- 1st 3Qtrs Business Results
January 24, 2005
- REGULATORY NEWS IN BRIEF
January 24, 2005
- Final Agreement Reached on Disclosure of Clinical Trial Information: 4 Major Drug Bodies
January 24, 2005
- JMA to Demand More Funds for Medical Services with People: Dr Uematsu
January 24, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
January 24, 2005
- 2005 to Be Decisive Year for Health Insurance Reform: Kenporen
January 24, 2005
- PRESS SEMINAR
January 24, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 24, 2005
- OTC NEWS IN BRIEF
January 24, 2005
- New Year's Gathering of 4 Tokyo-based Associations
January 24, 2005
- MEDICAL DEVICE NEWS IN BRIEF
January 24, 2005
- Leaders Outline Strategies for Survival in New Year's Addresses
January 24, 2005
- BULLETIN
January 24, 2005
- Aventis Pharma Aims to Strengthen Allegra's Leading Position
January 24, 2005
- BULLETIN
January 24, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…